Semaglutide and Loxenatide Trial Aims to Improve Cardiac Autonomic Neuropathy in Type 2 Diabetes

Diabetic cardiac autonomic neuropathy (DCAN) is a severe and often overlooked complication of Type 2 Diabetes, significantly increasing mortality risk. It manifests as issues like elevated resting heart rate, orthostatic hypotension, and heightened susceptibility to cardiac events. Current standard-of-care primarily focuses on glycemic control, which often falls short in fully addressing or reversing DCAN. Given the known cardiovascular benefits of GLP-1 receptor agonists (GLP-1RA), this study explores their potential to directly ameliorate cardiac nerve damage, addressing a critical gap in diabetes management.

This Phase 4 randomized controlled trial will enroll 60 adults (ages 18-80) with Type 2 Diabetes. Participants will be divided into two groups: one receiving standard diabetes care, and the other receiving standard care plus a once-weekly injection of either semaglutide or polyethylene glycol loxenatide for 6 months. Before and after the treatment period, subjects will undergo comprehensive assessments, including blood tests and non-invasive cardiac function evaluations. Key diagnostic tools include 24-hour heart rate variability monitoring and cardiac autonomic reflex tests to quantify changes in nerve function.

This ongoing Phase 4 clinical trial is designed to assess the impact of GLP-1RA treatment on cardiac autonomic function in Type 2 Diabetes. The primary objective is to determine if semaglutide or polyethylene glycol loxenatide can improve heart rate variability (HRV), a critical indicator of cardiac nerve health. Researchers will meticulously measure various HRV parameters, alongside secondary outcomes such as changes in body weight, glycemic control (e.g., HbA1c levels), and insulin resistance. The study aims to elucidate whether these GLP-1RAs offer protective or ameliorative effects against DCAN beyond their established metabolic benefits. Results are pending as the trial is currently recruiting participants, with an estimated completion date in late 2027. The findings will reveal if GLP-1RA therapy can significantly impact the progression or reversal of cardiac autonomic dysfunction.

The primary endpoint is improvement in heart rate variability, a key sign of heart nerve function, which will be assessed through 24-hour heart rate variability monitoring.